|J - Antiinfectives for Systemic Use|
Antiinfectives are also classified in the following groups:
A01AB Antiinfectives and antiseptics for local oral treatment
A02BD Combinations for eradication of Helicobacter pylori
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
D06 Antibiotics and chemotherapeutics for dermatological use
D07C Corticosteroids, combinations with antibiotics
D09AA Ointment dressings with antiinfectives
D10AF Antiinfectives for treatment of acne
G01 Gynecological antiinfectives and antiseptics
P Antiparasitic products, insecticides and repellents
R05X Other cold preparations
S03 Eye and ear preparations with antiinfectives
Even systemically administered antibacterials and antimycotics may be classified in other groups if their target is exclusively local, e.g. the skin - D01 - Antifungals for dermatological use
Inhaled antiinfectives are classified in J.
The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity. However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly. The DDDs assigned are based on daily treatment. The duration of the treatment periods is not taken into consideration. For antiinfectives given in a high initially starting dose followed by a lower daily "maintenance" dose, the DDDs are based on the "maintenance" dose if the total duration of the treat-ment course is more than one week. If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).
|J05 - Antivirals for Systemic Use|
This group comprises specific antiviral agents, excl. vaccines.
Antivirals for dermatological use, see D06BB.
Antivirals for ophthalmological use, see S01A - Antiinfectives.
Amantadine, which is also used as an antiviral agent, is classified in N04BB.
|J05A - Direct Acting Antivirals|
This group comprises agents acting directly on the virus.
|J05AG - Non-Nucleoside Reverse Transcriptase Inhibitors|
The DDDs are based on combination therapy in HIV infections.
|J05AG03 - Efavirenz|
|0.6 g||O|| |